Milestones

  • Licensed first in class dual IDO/TDO
    inhibitors patents to Roche

  • Developed and sold strategy for dual
    kinase inhibition to Medivation, USA

  • Selected by London Partners as one of
    “India’s Emerging 20” companies

  • Eight patents filed

About curadev

We are a small molecule drug discovery biotech with an exciting portfolio of research programs and patent protected drug candidates. Our programs seek to ameliorate disease by translating cutting edge discoveries into new medicines. Founded in 2010, Curadev's leadership team has created a premier translational research organization known for prescient target selection and high quality data-driven program execution. We have swiftly established our credentials by successfully creating and out-licensing our small molecule patents in immune-oncology to Roche.

science

Research Interests

Immune Oncology

We are fascinated by the ability of tumors to evade immune elimination. Most of our current programs focus on restoring the power of the immune system to achieve clean tumor kills. Tumors subvert immunity in a variety of ways. They can hide their very existence from innate cellular alarm systems and circulating surveillance immune cells, frustrate the buildup and amplification of immune responses and subvert established inflammatory responses by evoking potent immunosuppressive factors.

The recent approvals of inhibitors targeting checkpoint blockade are the first steps in the establishment of immuno-oncology as durable method of treating a number of cancers. The coming decade will see the emergence of new generations of immune system targeted oncology drugs which can be used as monotherapy or in combination with other immuno-oncology agents or existing drugs.

  • The IDO/TDO program focuses on relieving immune suppression caused by products of the kynurenine pathway. Greater than 90% of ingested tryptophan is metabolized through the kynurenine pathway by the heme containing oxidoreductase enzymes indoleamine 2,3 dioxygenase (IDO) and tryptophan 2,3 dioxygenase (TDO). High levels of tryptophan metabolites create a tolerogenic environment by increasing the number of circulating regulatory T cells and driving CD8+ T cells to apoptosis. Accessing the kynurenine pathway enables tumors to develop resistance to checkpoint blockade drugs that target CTLA4 or PD-L1/PD1. Curadev has developed potent small molecule drug candidates that reduce kynurenine levels in a range of experimental paradigms. These molecules fall into two classes – IDO specific inhibitors and first in class IDO/TDO dual inhibitors. The therapeutic goal is to combine these molecules with other immune check point inhibitors or specific cytotoxic therapies to potentiate immune response against various types of tumors.
  • The STING agonist program focuses on kick-starting an innate immune response in tumors which are devoid of a T cell infiltrate and are consequently immunologically silent. Generating a Type I interferon in these non-inflamed tumors leads to the activation of CD8α dendritic cells which recruit CD8 T-cells and initiate strong anti-tumor responses. We have designed and developed potent, non-nucleoside, classical small molecule agonists that activate all isoforms of human STING leading to robust secretion of Type 1 interferons and related cytokines.
  • The CDV16 program targets an enzyme that suppresses T cell priming and activation and down regulates the adaptive anti-tumor T cell response by triggering apoptosis in peripheral T cells. In the absence of proper co-stimulation T cell responses are naturally negatively regulated by activation induced cell death pathways (AICD) that suppress pro-inflammatory NFκB signaling. Tumors activate AICD to reduce the proliferation of T cells and negatively regulate the buildup of a T cell response. Inhibition of the AICD pathway generates a potent and sustained anti-tumor response in mice.
  • Cancer Metabolism

  • The CDV14 program focuses on the ability of tumors to survive in hostile microenvironments by altering their metabolic requirements. The inner tumor mass is a poorly vascularized, nutritionally barren hypoxic, hypoglycemic, hypolipidemic zone in which conventional cellular metabolism is dysregulated. However, certain tumor cells including cancer stem cells reprioritize the usage of internal metabolites and thrive in this environment. We have developed potent small molecule inhibitors of a enzyme that promotes tumor survival in these conditions. Combinations of these inhibitors with other forms of cancer therapy are being investigated to identify synergistic modes of tumor elimination.

Targeted Therapy

  • The aberrant activation of B-cells has been implicated in several types of cancers and hematological disorders. BTK and PI3Kδ are kinases responsible for B-cell signal transduction, and inhibitors of these enzymes have demonstrated clinical benefit in certain types of lymphoma.  We demonstrated synergistic killing of human lymphoma cells by combining single agent inhibitors and provided a rationale for the simultaneous inhibition of these pathways to generate more robust responses and to overcome potential resistance to single agent use.  This project was then presented to Medivation who launched a joint program with Curadev to identify dual inhibitors that would block both kinases. 

Neuroinflammation

  • We have initiated a collaboration at INSERM’s Hôpital Robert Debré with Professor Pierre Gressens, one of the leading researchers who established the importance of microglia and neuroinflammation as the underlying cause of diverse neuropathologies including perinatal brain injury and white matter damage. This partnership enhances our capacity for being at the cutting edge of academic research by providing us with a platform for discussions about critical results that give early clues on new pathways as well as current thinking in the field of neuro-immunology. We are able to do high and low throughput screens using several central nervous system derived human and mouse cell lines as well as validation in primary cultures and in-vivo disease models. For Curadev, this collaboration forms an important component of our early stage target identification program in the area of autoimmune diseases and cancers.
  • INSERM, Paris, France: In 2016 Curadev initiated a collaboration at INSERM’s Hôpital Robert Debré with Professor Pierre Gressens, one of the leading researchers who established the importance of microglia and neuroinflammation as the underlying cause of diverse neuropathologies including perinatal brain injury and white matter damage. This partnership enhances our capacity for being at the cutting edge of academic research by providing us with a platform for discussions about critical results that give early clues on new pathways as well as current thinking in the field of neuro-immunology. We are able to do high and low throughput screens using several central nervous system derived human and mouse cell lines as well as validation in primary cultures and in-vivo disease models. For Curadev, this collaboration forms an important component of our early stage target identification program in the area of autoimmune diseases and cancers.
  • All India Institute of Medical Sciences, New Delhi, India: Curadev is the industrial partner in a research collaboration between AIIMS and INSERM for the discovery of diagnostic markers for the early detection of fatal immune responses in acute myocardial infarction (AMI) patients. Professors Savita Yadav and Sandeep Singh of AIIMS and Professor Anne Marie Papini of INSERM are investigating the expression of proteins and/or aberrantly modified proteins that could have antigenic properties in AMI in order to correlate potential antibody responses with disease activity. Recognition of specific antibodies present in sera of AMI patients could have both a diagnostic and prognostic value. This project has attracted funding from CEFIPRA and the Department of Biotechnology’s BIRAC program.
  • Indian Institute of Technology, Kanpur, India: In 2010 Curadev embarked on three year collaboration at IIT Kanpur where it incubated a part of its early internal chemistry team under a program run by SIDBI Incubation Center to catalyze innovation. It was greatly satisfying when we were able to provide a significant financial reward to IIT Kanpur and the faculty associated with our program for their assistance in getting Curadev off the ground.
AACR (2014) Tumor Immunology and Immunotherapy: A New Chapter
View
AACR (2016) Annual Meeting
View
Bioorganic & Medicinal Chemistry Letters 26 (2016) 5103–5109
View
ACS Med. Chem. Lett. October 28, 2016
View

TEAM

Curadev attracts passionate, creative people and builds extraordinarily productive teams. Through a careful recruiting process, Curadev has built a well-knit team of scientific investigators who thrive on the constant challenges of drug discovery research.

Curadev has a world-class scientific advisory board that works in close association with Curadev scientists to identify new research directions and accelerate Curadev’s target validation and drug discovery programs.


NEWS

CORPORATE SOCIAL RESPONSIBILITY

Curadev under its CSR program, sponsored the Impact India’s 172nd Lifeline Express (World’s First Hospital Train) project at Gondia in Maharashtra from May 4 to 25, 2016. The aim of the Lifeline Express is to deliver quality medical and surgical services in rural and remote areas of our country.

Contact us


Curadev Pharma Private Limited


B 87, Sector 83
Noida, UP 201305 INDIA

Tel: +91-120-408 1818/19
Fax: +91-120-408 1820

View Map

EMAIL:
For Investment, Partnering & Collaboration enquiries: business@curadev.in
For all other enquiries: interact@curadev.in

Contact us


Curadev Pharma Ltd.


Office 28, Innovation House Discovery Park,
Sandwich, Kent, CT13 9ND, United Kingdom

Tel: +44 (0) 1304 806842

View Map